POC Study to Evaluate BSI-045B in Moderate-to-severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

22

Participants

Timeline

Start Date

July 31, 2023

Primary Completion Date

September 18, 2024

Study Completion Date

September 18, 2024

Conditions
Atopic Dermatitis
Interventions
DRUG

BSI-045B

Patients will be treated with BSI-045B.

Trial Locations (17)

10075

Sadick Research Group, New York

19103

Paddington Testing Company, Philadelphia

20037

The George Washington University School of Medicine and Health Science, Washington D.C.

27518

Accellacare - Cary, Cary

27609

Accellacare - Raleigh, Raleigh

28411

Accellacare-Wilmington, Wilmington

30328

Advanced Medical Research - Medical Dermatology Specialists, Sandy Springs

40217

Skin Sciences/Derm Research Pllc., Louisville

45324

Wright State Physicians Health Center, Fairborn

46250

Dawes Fretzin Clinical Research, Indianapolis

77598

Center for Clinical Studies - Webster, Webster

92056

Profound Research LLC - Nashville - Corporate, Oceanside

92708

First OC Dermatology - Fountain Valley, Fountain Valley

94538

Center for Dermatology Clinical Research, Fremont

99202

Dermatology Specialists of Spokane, Spokane

01915

Allcutis Research - Beverly, MA, Beverly

02169

Beacon Clinical Research, Quincy

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Biosion, Inc.

INDUSTRY